Vyvanse FDA Approval History: Every Regulatory Milestone from 2007 to Generic Entry

Lisdexamfetamine dimesylate, sold under the brand name Vyvanse, is a central nervous system stimulant in the amphetamine class. It is chemically distinct from immediate-release dextroamphetamine and mixed amphetamine salts (Adderall) because it is administered as an inactive prodrug: the parent molecule has no stimulant activity until red blood cell enzymes cleave it to release d-amphetamine. This is a real pharmacologic difference from other stimulants, not a marketing distinction, and it is the basis for several of the regulatory decisions described below.

The thesis of this page is narrow but specific: the useful question about Vyvanse's regulatory record is not simply "when was it approved," but what each approval milestone actually authorized versus what it is commonly assumed to mean. The BED indication is frequently misread as a weight-loss endorsement, and the prodrug design is frequently oversold as an abuse-proof formulation. Neither reading survives contact with the FDA label.

What the FDA has confirmed, in order

2007, ADHD in children. The FDA approved NDA 021977 on February 23, 2007, for ADHD in children ages 6 through 12. This was the first lisdexamfetamine product approved for U.S. marketing. The original applicant was New River Pharmaceuticals; Shire acquired the company shortly after approval and has held the marketing rights since, later passing to Takeda when Takeda acquired Shire. Readers who want the primary regulatory record, including approval letters and label history, can consult Drugs@FDA for NDA 021977 directly.

2008, adult ADHD. The label was expanded to cover ADHD in adults 18 and older. This made lisdexamfetamine one of the stimulants with a specific adult indication at a time when several competing products were still labeled primarily for pediatric use.

2015, binge eating disorder. On January 30, 2015, the FDA approved lisdexamfetamine for moderate-to-severe BED in adults. This is described directly in the agency's own announcement of the approval. At the time, and still as of this writing, it is the only medication carrying a specific FDA-approved BED indication. The label states plainly that the drug is not indicated for weight loss, and the agency required that language after its advisory committee raised concern that the BED approval could be marketed or used as a weight-management tool. The BED indication does not extend to children or adolescents.

2017, chewable tablet. The FDA approved a chewable tablet formulation as an additional dosage form for patients who have difficulty swallowing capsules.

2023, generic entry. Lisdexamfetamine's primary composition-of-matter patent protection ended, and generic versions entered the U.S. market that year. The FDA Orange Book is the authoritative source for which manufacturers hold approved ANDAs and their therapeutic equivalence ratings; consult it directly for the current list, since generic entries have continued to change since 2023 and this page should not be treated as a static roster.

This compact set of facts is the load-bearing part of the page: Vyvanse was approved for pediatric ADHD in 2007, adult ADHD in 2008, and moderate-to-severe BED in adults in 2015, it has never carried a weight-loss indication, and generic lisdexamfetamine became available in 2023 after patent expiration, per FDA and Orange Book records.

The prodrug design: a real pharmacokinetic difference, not an abuse-proof guarantee

Lisdexamfetamine's inactive-until-metabolized design was intended to produce a more gradual onset and a pharmacokinetic profile that is harder to exploit through non-oral routes (crushing and snorting or injecting) than immediate-release amphetamine. Human abuse-liability studies comparing intravenous lisdexamfetamine to intravenous d-amphetamine have been published, and the FDA-approved label does contain language reflecting reduced abuse-related subjective effects when the drug is given intravenously. Readers should treat the specific numeric findings of those studies (sample sizes, effect sizes, statistical comparisons) as requiring verification against the original publication rather than restated exactly here, since the identifiers commonly attached to this claim across secondary sources are not reliably matched to the correct paper.

What is not in dispute: lisdexamfetamine remains a Schedule II controlled substance. The DEA treats it identically to other Schedule II amphetamines for prescribing and dispensing purposes, including the requirement in most states for a new written or electronic prescription at each fill, with no refills. The prodrug mechanism may reduce certain routes of misuse, but it does not remove the drug from the highest non-narcotic control schedule, and prescribers should not treat the design as a substitute for standard controlled-substance precautions, including screening for personal or family history of substance use disorder.

A quotation attributed to a named physician appeared in an earlier version of this content without a verifiable source. It has been removed rather than repeated, because an unverifiable quotation is worse than no quotation on a medical page.

Binge eating disorder approval: what the trials showed and what remains to be verified

Three randomized, placebo-controlled trials supported the 2015 BED approval, two of them near-identical pivotal studies and one long-term relapse-prevention study. In general terms, the pivotal trials enrolled adults with moderate-to-severe BED (defined by a minimum frequency of binge days per week) and found that lisdexamfetamine at doses in the 50 mg to 70 mg range reduced binge eating days per week substantially more than placebo over about 12 weeks, with the higher dose associated with a meaningfully higher rate of patients reaching zero binge days. A separate maintenance-phase study found that patients who had responded to open-label treatment and were then withdrawn to placebo relapsed at a much higher rate than those continued on active treatment.

Those directional findings are consistent with what the FDA cited in approving the indication. The exact percentages and confidence intervals that circulate for these trials (specific binge-day reductions, cessation rates, relapse rates) should be confirmed against the original JAMA Psychiatry publications before being used in a clinical or patient-facing context, because the identifiers attached to this claim in earlier drafts of this content could not be independently verified for this revision.

Post-market safety: what has changed on the label since 2007

Amphetamine-class labeling, including Vyvanse's, carries a boxed warning about the potential for abuse and dependence. Since 2007, post-market experience has led to several areas of continued attention rather than dramatic label overhauls:

• Cardiovascular risk. Regulators and researchers have looked repeatedly at whether stimulant treatment increases the risk of serious cardiovascular events in adults. Findings across this literature have generally not supported a strong signal in typical treatment populations, but the label retains cardiovascular precaution language and recommends baseline cardiac history assessment before starting treatment. Readers should check the current FDA label and FDA Drug Safety and Availability page for the latest communications rather than relying on any single historical study.
• Psychiatric adverse events. Amphetamine-class labeling includes warnings about treatment-emergent psychosis and mania, and comparative observational research has examined whether amphetamine products carry a different psychiatric risk profile than methylphenidate-class stimulants. The direction of this research has supported continued psychiatric monitoring during stimulant therapy; specific relative-risk figures require verification against the original publication before being treated as settled numbers.
• Serotonin syndrome. Amphetamine-class labels, as a class, address the risk of serotonin syndrome when combined with serotonergic medications such as SSRIs, SNRIs, and triptans. The specific FDA communication that introduced this language for Vyvanse could not be verified against a matching source for this revision; readers who need the exact date and wording should consult the current prescribing information directly rather than a secondary summary.
• Growth in children. Long-term pediatric use has been associated with a degree of growth suppression relative to normative growth curves, which is why the label recommends periodic monitoring of height and weight during continuous treatment. The precise magnitude reported in any single study should be checked against the source trial rather than quoted as a fixed number, since growth effects vary by study duration and population.

What generic entry changed, and what it didn't

Generic lisdexamfetamine reached the market in 2023 after patent expiration, and additional manufacturers have received approval since then. Generic versions rated AB in the Orange Book are considered by the FDA to be therapeutically equivalent to the brand, meaning they must demonstrate equivalent rate and extent of absorption. Some patients report subjective differences after switching from brand to generic stimulant products; bioequivalence testing does not guarantee an identical subjective experience for every individual, even when it satisfies the FDA's statistical equivalence standard.

Claims about exact pricing changes, total sales figures, or prescription volume attached to the generic transition are commercially and time sensitive, and this draft does not restate specific dollar or unit figures because they could not be verified against a primary source for this revision. Readers who need current pricing or market-share data should consult a pharmacy benefit or market-research source directly, since these figures change year to year and were not confirmed here as of the last review date above.

Evidence boundary: established, plausible, and unresolved

Established from FDA records. The approval dates and indications described above (2007 pediatric ADHD, 2008 adult ADHD, 2015 BED, 2017 chewable tablet, 2023 generic entry) are consistent with the public regulatory record and can be checked directly against Drugs@FDA and the Orange Book. The absence of a weight-loss indication is also established; the label states it explicitly.

Plausible but requiring primary-source confirmation on this page. The specific numeric findings from the pivotal ADHD and BED trials (sample sizes, exact effect sizes, percentage reductions, relative-risk figures from safety studies) are consistent in direction with what regulators cited when approving each indication, but the precise figures in this revision have been generalized rather than restated as exact numbers, because the citation identifiers inherited from prior drafts could not be verified as pointing to the correct papers.

Not established from anything in this article. Whether the prodrug design meaningfully reduces real-world diversion or misuse at a population level, as opposed to blunting subjective effects in controlled abuse-liability studies, is not something this page's sources can answer. Current pricing, sales volume, and state-by-state e-prescribing mandates are also outside what this page verifies, since those facts are volatile and were not confirmed against a live source at the time of this review.

A decision framework for reading any Vyvanse regulatory claim

Use this sequence when you encounter a claim about Vyvanse's approval history, whether from a pharmacy handout, a forum post, or a marketing page, before treating it as settled:

1. Is the claim about what the FDA approved, or about what a study found? FDA approval claims (indication, age range, dosage form, schedule) are checkable against Drugs@FDA and the current label. Study findings (effect sizes, percentages, risk ratios) require the original publication, not a secondary restatement.
2. Does the claim involve weight loss? If any source implies Vyvanse is approved or appropriate for weight management outside the specific BED indication, that claim is inconsistent with the FDA label and should be treated as incorrect, dated May 2026.
3. Does the claim treat the prodrug design as eliminating abuse risk? If so, narrow it. The evidence supports reduced subjective effects in controlled intravenous abuse-liability testing, not elimination of Schedule II risk or real-world diversion potential.
4. Is the claim price- or supply-related? Generic pricing, market share, and availability change often. Treat any specific dollar figure or percentage discount as needing a same-week source check rather than a citation from an older article, including this one.
5. Is the claim a specific statistic (a percentage, a hazard ratio, a sample size) attached to a named trial? Confirm it against the named journal directly. A plausible-sounding statistic attached to a real journal name is not the same as a verified statistic.

Common reader questions

When to seek urgent or individualized care

This is a regulatory history page, not dosing or diagnostic guidance. Anyone experiencing chest pain, fainting, signs of psychosis, suicidal thoughts, or symptoms of serotonin syndrome (agitation, high fever, muscle rigidity, rapid heart rate) while taking lisdexamfetamine or any amphetamine product needs urgent medical evaluation rather than a review of this article. Questions about starting, stopping, or adjusting a specific dose belong with the prescribing clinician, since individualized dosing depends on factors this page does not and cannot assess.